Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review by Ogilvie, Isla et al.
RESEARCH ARTICLE Open Access
Burden of community-acquired and nosocomial
rotavirus gastroenteritis in the pediatric
population of Western Europe: a scoping review
Isla Ogilvie
1, Hanane Khoury
1*, Mireille M Goetghebeur
1, Antoine C El Khoury
2 and Carlo Giaquinto
3
Abstract
Background: Rotavirus affects 95% of children worldwide by age 5 years and is the leading cause of severe
dehydrating diarrhea. The objective of this review was to estimate the burden of rotavirus gastroenteritis (RVGE) in
the Western European pediatric population.
Methods: A comprehensive literature search (1999-2010) was conducted in PubMed and other sources (CDC;
WHO, others). Data on the epidemiology and burden of RVGE among children < 5 years-old in Western Europe
–including hospital-acquired disease–were extracted.
Results: 76 studies from 16 countries were identified. The mean percentage of acute gastroenteritis (AGE) cases
caused by rotavirus ranged from 25.3%-63.5% in children < 5 years of age, peaking during winter. Incidence rates
of RVGE ranged from 1.33-4.96 cases/100 person- years. Hospitalization rates for RVGE ranged from 7% to 81%
among infected children, depending on the country. Nosocomial RVGE accounted for 47%-69% of all hospital-
acquired AGE and prolonged hospital stays by 4-12 days. Each year, RVGE incurred $0.54- $53.6 million in direct
medical costs and $1.7-$22.4 million in indirect costs in the 16 countries studied. Full serotyping data was available
for 8 countries. G1P[8], G2P[4], G9P[8], and G3P[8] were the most prevalent serotypes (cumulative frequency: 57.2%-
98.7%). Serotype distribution in nosocomial RVGE was similar.
Conclusions: This review confirms that RVGE is a common disease associated with significant morbidity and costs
across Western Europe. A vaccine protecting against multiple serotypes may decrease the epidemiological and cost
burden of RVGE in Western Europe.
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Background
Rotavirus affects 95% of all non-vaccinated children
w o r l d w i d eb yt h ea g eo ff i v ey e a r s ,a n di st h el e a d i n g
cause of severe dehydrating diarrhea in that age group
[1,2]. Among the 23.6 million children under five years
of age in the European Union, it is estimated that 3.6
million episodes of rotavirus gastroenteritis (RVGE)
occur annually [3]. Transmitted by the fecal-oral route,
most rotavirus infections are community-acquired, how-
ever nosocomial infections are a major component of
hospital-acquired infectionsi nc h i l d r e n[ 4 ] .I nar e v i e w
from six countries in Europe in 2006, RVGE was
reported as the major etiologic agent of pediatric noso-
comial diarrhea, accounting for 31-87% of cases [4].
Rotavirus infection peaks in the winter months
between November and February in temperate climates
[1,4,5]. The predominance of a particular rotavirus gen-
otype combination during an RVGE season may vary
between geographical areas, and from one season to the
next [6]. Of the seven sero-groups of rotavirus (groups
A-G), three are capable of affecting humans (groups A-
C). Group A rotavirus infections are the most common
[5]; they are further classified into G- and P-types [7].
Rotavirus carrying either G1, G2, G3, G4, or G9 geno-
types combined with P[4] or P[8] genotypes are cur-
rently the most common causes of RVGE in humans
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in Europe, with G12 an emergent genotype [8].
Within the European Union, RVGE is estimated to
occur at a rate of 1 symptomatic infection in every 7
children each year, accounting for 231 deaths, more
than 87,000 hospitalizations and almost 700,000 outpati-
ent visits [3]. Many episodes of RVGE are mild enough
to be managed at home, however, within Europe,
approximately 20% of children will see a medical practi-
tioner during the illness, and an estimated 1 in 54 cases
will result in hospitalization [3]. RVGE imposes a heavy
economic burden by incurring not only direct (consulta-
tion, emergency, hospitalization, medication) costs, but
also indirect costs (parent work days lost, childcare,
etc....) [3,9,10].
Objectives of study
The objective of this study was to carry out a compre-
h e n s i v es c o p i n gr e v i e wo ft h er e c e n tl i t e r a t u r eo nt h e
burden of pediatric RVGE, both nosocomial and com-
munity-acquired, in Western Europe. We examined the
epidemiology of RVGE, the distribution of rotavirus gen-
otype combinations, morbidity and mortality due to
RVGE, resources utilization and costs by country and
according to healthcare setting.
Methods
Literature search strategy
A comprehensive literature search was conducted for
studies pertaining to the burden of rotavirus infection
on the pediatric population in Western Europe (< 5
years, unless otherwise specified). The searches, limited
to articles published between 1
st January 1999 and 1
st
May 2010, were carried out in the National Library of
Medicine’s Pubmed, the Center for Disease Control
(CDC) rotavirus global surveillance http://www.cdc.gov/
rotavirus/global_surveillance/surveillance.htm, and the
World Health Organization (WHO) http://www.who.int/
nuvi/rotavirus/en/. Studies were included if they were
set in the following countries: Austria, Belgium, Den-
mark, Finland, France, Germany, Greece, Ireland, Italy,
the Netherlands, Norway, Portugal, Spain, Sweden, Swit-
zerland and the United Kingdom (UK). The search
terms used for this scoping review included: rotavirus,
outcome, mortality, death, incidence, prevalence, noso-
comial, home care, serotype, strain, cost, economic, bur-
den, and resource use, where the asterisk represents a
wildcard. English language articles were primarily
reviewed along with promising articles in other lan-
guages. In addition, records were searched manually to
identify the most relevant studies pertaining to the
object of this document and bibliographies of retrieved
articles were screened to identify additional sources of
information.
Data extraction and analysis
For all studies, the dates reported refer to when studies
were conducted, which was often several years before
the publication date. Where data was available for an
individual country within a multicountry study, both
overall and data delineated by country were extracted.
Where available, information was reported for both
community-acquired and nosocomial RVGE, and from
hospital, primary care or home care settings. An RVGE
episode was considered to be nosocomial (hospital-
acquired) if gastroenteritis symptoms occurred at least
48 h after children were admitted to hospital for a diag-
nosis other than diarrhea [4].
Epidemiology of RVGE
Incidence data was extracted as cases of RVGE per 100
patient-years for countries of interest. Information on
incidence from studies conducted in a day-care setting
and for nosocomial infection was captured separately.
Where incidence data was reported as per child month,
the original data were reported. In addition data was
converted to person-years, for ease of comparison
between settings. Likewise, incidence of nosocomial dis-
ease reported as cases per 1000 days of hospitalization
was also provided as cases per 100 person-years in
hospital.
The proportion of RVGE among cases of acute gastro-
enteritis was extracted. In the case where several surveil-
lance studies were published for a single country, a
pooled average of the proportion of RVGE among cases
of acute gastroenteritis was calculated and reported,
along with ranges across studies for each country. If
available, the variation over time in the proportion of
RVGE among cases of gastroenteritis was captured.
Data on infection seasonality was collected and
reported.
Rotavirus genotype combinations
The proportion of each genotype combination among
genotyped RVGE samples was extracted, where avail-
able. The most recently available studies from each
country were used to gather information about the dis-
tribution of genotype combinations across the countries
of interest. In addition, data concerning changes in the
prevalence of genotype combinations over time was col-
lected, as was any reference to emerging serotypes.
Morbidity and mortality
To assess disease severity, two types of data were
extracted, where available. Firstly, the severity and pro-
portion of patients suffering from dehydration due to
RVGE was captured and secondly, disease severity as
measured by the 20-point Vesikari scoring system [11].
The Vesikari scale is based on the duration and intensity
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tion, and need for treatment and hospitalization [11]. A
Vesikari score ≥ 11 is indicative of severe disease [11].
Mortality due to RVGE was captured as annual fatal-
ities and mortality rates per 100,000 children less than
five years of age.
Disease burden
For healthcare resource utilization, data on hospital
admission rates, need for intravenous rehydration, and
duration of hospital stay were collected. Hospitalization
due to RVGE was defined as hospital admission of chil-
dren presenting to hospital with severe acute commu-
nity-acquired RVGE [12]. Cost-of-illness data captured
included direct medical costs, out-of-pocket expendi-
tures, and indirect costs attributed to lost productivity by
parents of children suffering from RVGE. Costs are
reported in 2009 US dollars (1 $US equals 0.721189 € [1
st
Jan 2009]) [13]. In addition, where a national cost esti-
mate for the total cost of RVGE was available, we have
presented the total cost of illness as a proportion of the
gross national product of that country, to enable compar-
ison between countries. The gross national product for
each country for 2009 was obtained from the World
Bank at http://data.worldbank.org/data-catalog[14].
Results
Literature review
Study selection
As shown in Figure 1, a total of 76 studies containing
relevant data pertaining to RVGE in children under five
years of age were captured. Studies were included on
the following topics: incidence (n = 16 studies), propor-
tion of RVGE among cases of acute gastroenteritis (n =
38 studies), seasonality of RVGE infection (n = 36 stu-
dies), serotype distribution (n = 25), disease severity (n
= 20), mortality (n = 9), healthcare resource utilization
(n = 36), and costs (n = 17). More than one type of data
was available from a single study; hence the total num-
ber of studies is not the sum of those for each topic. A
study was excluded if it was not carried out in humans,
was a duplicate of what was already included, was not
from a country of interest, did not include children
under five years of age, if there were no original data (i.
e. a review), or if data did not meet the criteria given
above.
Overview of evidence available
An overview of the evidence available for each country
is presented in Table 1, and detail about each study
selected is given in the Additional file 1. Epidemiological
data for RVGE in Western Europe was available from a
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Figure 1 PRISMA diagram of studies selected.
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Country Epidemiology Genotype
combination data
Morbidity and Mortality Disease Burden
Incidence Proportion RVGE Seasonality Disease severity Mortality Resource utilization Costs
Multic
ountry*
15**,1 6
¶,2 5
║ 25
║,34
¶,85
§ 15**,16
¶,25
║,36
‡ 15**,25
║,3 6
‡,92
†,93
¶ 15**,25
║,34
¶ 78
†† 15**,25
║,34
¶,85
§ 83
¶
Austria 15**,31 31 15**,31 62 31,76 78
†† 76
Belgium 16
¶ 34
¶ 16
¶ 93
¶,94 81 78
†† 81,85
§ 81,83
¶
Denmark 45,96 36
‡,12 95 78
†† 45, 85
§,95,96 45
Finland 23 78
†† 23,76
§
France 16
¶,17,20,21,25
║,26,27,28 17,25
║,34
¶,26,27,28,37,38,40,
41,49,97,98
16
¶,17,20,21,25
║,26,27,36
‡,39,
40,41,98
17,20,25
║,36
‡,63,93
¶ 17,20,26,37,38,49,79 17,26,78
†† 17,20,21,26,27,34
¶,37,38,3
9,49,79,85
§,87
20,21,27,38,74
¶,87,98
Germany 15**,1 6
¶,18,25
║ 25
║,34
¶,42,50 15**,16
¶,18,25
║,42 25
║,50,93
¶ 42,78
††,9
9
34
¶,42,85
§ 83
¶
Greece 46,47 46,47 46 78
†† 46,85
§
Ireland 44 77 78
†† 44,77,85
§ 77
Italy 16
¶,19, 25
║,32 19,25
║,32,34
¶,51,52, 53,100 16
¶,19,25
║,3 2,36
‡,51,100 19,25
║,51, 60,65,68,9
3
¶
19,51, 82 19,32,34
¶,52,82,85
§ 32,82, 83
¶
Netherl
ands
101 78
†† 85§
Norway 102,103 103 102 78
††
Portugal 61,104 104 61,104 78
††
Scandinavia 36
†
Spain 16
¶,25
║,29,30,33 25
║,29,30,32,34
¶,54,55,56 16
¶,25
║,29,30,33,36
‡,54,90,105 25
║,30,36
‡, 55,64,93
¶ 29,3
0,56,78
††,
29,30,34
¶,56,85
§,89, 90,105 29,56,83
¶,89, 90
Sweden 16
¶ 34
¶ 16
¶ 93
¶ 43 78
†† 34
¶,85
§ 83
¶
Switzerland 15** 15**
UK 16
¶,25
║ 34
¶,57,58,59 16
¶,25
║,36
‡,57 25
║,36
‡,57,58,93
¶ 78
††,106 34
¶,85
§,91, 106 83
¶,91
*Where data was available for individual countries within a multicountry study, it has been extracted. Therefore, the relevant reference has been added to individual countries above
†Denmark, Finland, Germany, Hungary, Italy, Netherlands, Slovenia, Spain, Sweden, Bulgaria, Lithuania, Belgium, UK
‡Denmark, France, Italy, Scandinavia, Spain, UK
§Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Spain, Sweden, UK, Overall data WHO European region
║Western Europe, France, Germany, Italy, Spain, UK
¶Belgium, France, Germany, Italy, Spain, Sweden, UK
**Austria, Switzerland and Germany
††Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, Sweden, UK
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4total of 52 studies covering incidence, the proportion of
RVGE among acute gastroenteritis cases, and seasonality
of infection.
Epidemiology of RVGE
Incidence of community-acquired RVGE
The annual incidence of community-acquired RVGE
among children under five years of age (per 100 person
years) was reported in seven countries [15-19], ranging
from 1.33 cases per 100 person-years (in Austria) to
4.96 cases per 100 person-years (in France) [15-19]. The
incidence of RVGE was approximately 12-fold higher
among children under three years of age in a daycare
setting–between 2.2 and 2.5 cases per 100 child-months
(26.4-30 cases per 100 person-years)–than for children
in community-based studies [20,21].
Home care setting A high number of children with
RVGE are not sick enough to be admitted to hospital
and many patients receive no medical care [22]. Since
rotavirus infection is not a notifiable disease and the
exact diagnosis is not needed for individual patient man-
agement, the incidence rates given above may be an
underestimate of the total disease incidence, and refer
only to patients requiring medical attention. Examina-
tion of the literature showed that data concerning
RVGE patients treated at home is sparse, most studies
estimated the proportion of patients with RVGE receiv-
ing home care. For Europe, estimations of the propor-
tion of RVGE patients receiving no medical care ranged
from 25% to 51% of patients [3,23,24]. Two studies from
a day care setting in France reported that 34.6% and
14.3% of RVGE cases, respectively, did not seek medical
attention [20,21].
Incidence of nosocomial RVGE
The incidence of nosocomial infection with RVGE
reported among the hospitalized pediatric population
was also higher than the incidence reported in commu-
nity based studies [25]. A prospective study by Forster
et al. that examined the incidence of RVGE among
patients under five years old in hospitals from five coun-
tries (France, Germany, Italy, Spain and the UK)
reported an overall incidence of nosocomial RVGE of
0.46 per 1000 days of hospitalization (16.8 per 100 per-
son-years in hospital) [25]. The range across countries
varied from 0 to 1.87 cases per 1000 days of hospitaliza-
tion (0-68.2 per 100 person-years in hospital) [25].
Other studies from Austria, France, Germany, Italy,
Spain, and Switzerland reported incidence rates for
nosocomial RVGE within the range reported by the For-
ster study [15,26-33].
Proportion of community-acquired RVGE
When limited to those studies that reported the propor-
tion of community-acquired RVGE among reported gas-
troenteritis cases for children under five years of age,
the mean percentage of cases caused by rotavirus infec-
tion ranged from 25.3% to 63.5%. Greece reported the
lowest proportion (25.3%), while those with the highest
proportion included Norway (63.5%) and Sweden
(52.0%). The remainder of the countries reported a per-
centage of between 36% and 45% (Figure 2). These rates
vary greatly depending on whether patients are seen in
hospital, emergency room, or primary care physician
clinic.
The REVEAL study, carried out in Belgium, France,
Germany, Italy, Spain, Sweden, and the UK, reported
that RVGE in children under five years of age was
responsible for between 53.0% and 68.9% of cases pre-
senting to hospitals, 35.4% and 63.3% for those seen in
emergency departments, and 7.7% and 41.3% of cases
seeking primary care physicians [34]. A second prospec-
tive multicenter study of children under five years of
age from France, Germany, Italy, Spain and the UK
reported that the overall proportion of community-
acquired rotavirus infections among reported hospita-
lized and ED acute gastroenteritis cases across the five
countries was 43.4% [25]. Most of these cases (80.9%)
occurred in children under 2 years of age [25]. In the
REVEAL study, 86.1% of RVGE cases occurred in chil-
dren aged between 3 months and 3 years of age while a
larger study from EuroRotaNet reported that 81.5% of
cases from 19 European countries were in patients
under 2.5 years of age [35,36].
Proportion of nosocomial RVGE
Only a few methodologically weak studies were identi-
fied relating to the prevalence of nosocomial RVGE
among children hospitalized for other conditions, or the
proportion of acute nosocomial gastroenteritis that was
due to rotavirus. In the original reports, nosocomial
RVGE was generally defined as disease occurring
between 48 to 72 h after admission of the child to hos-
pital, depending on the study [15,26,37]. The prevalence
of nosocomial rotavirus infections among hospitalized
children admitted for a diagnosis other than diarrhea
ranged from 2.9% to 6.6% in four studies from France
[26,27,37,38]. Three studies from five countries (Austria,
France, Germany, Spain and Switzerland) examined the
proportion of nosocomial RVGE among cases of acute
nosocomial gastroenteritis [15,26,30]. Nosocomial RVGE
accounted for between 47% and 69% of all hospital-
acquired acute gastroenteritis among hospitalized chil-
dren in the studies covering Austria, Germany, Spain
and Switzerland [15,30]. In one French study conducted
in 1999 during the peak of the rotavirus season, 97.8%
of nosocomial diarrhea cases were due to rotavirus [26].
A comparison of community-acquired RVGE and noso-
comial RVGE was carried out in a study from Austria,
Germany and Switzerland [15]. Rotavirus was detected
in 29.5%, 27% and 37.5% of children with community-
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Page 5 of 14acquired gastroenteritis, and in 57%, 69% and 49% of
children with nosocomial gastroenteritis, in Austria,
Germany and Switzerland, respectively [15]. The season-
ality of nosocomial RVGE mirrored that of RVGE in the
broader community, with most infections taking place
in the winter months [15,25-27,29,30,39-42].
Patients with nosocomial disease were generally
younger than those who acquired RVGE in the com-
munity [15,26,29,42,43]. Between 42.7% and 69.9% of
children affected by nosocomial RVGE were under 6
months of age (mainly neonates) compared with 15.9%
to 33.6% of patients with community-acquired disease
[25,42]. Across three studies covering five countries
(Austria, France, Switzerland, Germany and Sweden),
the median age of patients with nosocomial RVGE was
between 2.8 and 9 months compared to a median age
of between 12.5 and 16.7 months for patients with
community-acquired RVGE [15,39,43]. Four risk fac-
tors were reported to be strongly associated with noso-
comial RVGE in neonatal intensive care units
including premature birth (Odds Ratio [OR]: 2.63; P <
0.001), infections other than rotavirus (OR: 2.35; P <
0.01), malformation (OR: 2.38; P < 0.01), and changes
in glycemia and/or presence of jaundice (OR: 7.63; P <
0.001) [33].
Seasonality of RVGE
For most countries in Western Europe, RVGE was
reported to occur most often during the winter and
spring, from December to April or May. A slightly later
rotavirus season was noted in Ireland (February to
June), Greece (January to April), and Scandinavian
countries (Denmark: January to June; Norway: March to
May; Sweden: April) [23,36,44-48] No clear trend was
found in relation to geographical or climatological
parameters.
Rotavirus genotype combinations
Distribution of genotype combinations
Community-acquired RVGE The predominant serotype
of rotavirus causing RVGE varies from country to coun-
try and from year to year. The most recent serotype
data from each country is presented here. Only one gen-
otype combination (G1P[8]) was reported in all eight
countries for which full serotyping data is available
(Austria, Denmark, France, Germany, Italy, Portugal,
Spain and the UK). G1P[8] was the most common geno-
type combination in Austria [15], Denmark [36]. France
[36], Germany [25], Spain [25,36], and the UK [36],
accounting for between 48.6% and 84.7% of genotyped
RVGE samples in those countries.
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Page 6 of 14Nosocomial RVGE The distribution of rotavirus geno-
type combinations among patients with nosocomial
RVGE was reported in four studies covering seven coun-
tries (Austria, France, Germany, Italy, Spain Switzerland
and the UK) [15,25,30,49]. In general, the distribution of
rotavirus genotype combinations among patients with
nosocomial RVGE was very similar to the distribution
among patients with community-acquired disease from
the same study [15,25,30,49]. For example, in a prospec-
tive multicenter study from France, Germany, Italy,
Spain and the UK, G1P[8] accounted for 40.3% of geno-
typed samples among patients with community-acquired
RVGE and 35% of nosocomial RVGE [25]. Similarly in
the same study, G9P[8] accounted for 31.2% of commu-
nity-acquired RVGE and 36.3% of nosocomial RVGE,
and the proportions of other genotype combinations
were similar [25].
Evolution over time of genotype combinations
Community-acquired RVGE Information concerning
serotype distribution over time for fully serotyped sam-
ples from children under five years of age was available
for five countries (Denmark [36,50], France [25,36,51],
Italy [25,52,53], Spain [25,30,36,54], and the UK
[25,36,55,56]) (Figure 3). However, on examination of
the evolution of genotype distribution and predomi-
nance over time, we were not able to discern any overall
trends in serotype distribution within the region. This is
because serotype predominance appears to change on a
season to season basis within each country, and may
even differ from region to region within the same
country.
Nosocomial RVGE No studies examined the distribu-
tion of genotype combinations among patients with
nosocomial RVGE over time.
Emerging rotavirus serotypes in Western Europe
Four studies, three from Italy and one from Spain
described the emergence of new rotavirus serotypes in
Western Europe [52,54,57,58]. The emergence of the G9
serotype was documented in the winter season of 1999-
2000 in Southern Italy (19% of all rotaviruses) [59],
becoming then most prevalent in other European
regions An earlier study from Barcelona, Spain, docu-
mented an increase in the levels of strains G1P[4] and
G3P[4], which were considered uncommon at the time
of the study (1998-1999). Additionally, two G5 strains
were isolated in Barcelona; the origin of these G5 strains
(porcine or human) was unclear [54]. G12P[8], an emer-
ging potential human pathogen,[8] was documented in
Denmark in 2002 (4.1% of all rotaviruses) and the UK
(2.4%),[36] and was detected in very small proportions
(< 1%) in France[36,51] and Spain [36].
Morbidity and mortality
Disease severity
Community-acquired RVGE D i s e a s es e v e r i t ya s s e s s -
ment using the 20-point Vesikari scale was reported by
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Page 7 of 14seven studies covering eight countries
[15,17,20,25,31,46]. In France and Greece, the propor-
tion of children infected by rotavirus having moderate
to severe gastroenteritis was significantly higher com-
pared to children with non-rotavirus infection (82.8% vs
37.2% [P < .0001] in France; 65.4% vs 41.2% [P <. 0 1 ]i n
Greece) [17,46]. The proportion of patients presenting
to hospitals with severe acute community-acquired
RVGE (Vesikari score ≥ 11) was between 29% and 55%
in a study covering Austria, Germany, and Switzerland;
a study set in France, Italy, Spain and the UK reported
an overall proportion of severe disease of 53.3% [15,25].
Nosocomial RVGE For patients with hospital-acquired
infection, the overall proportion of patients with severe
RVGE in France, Italy, Spain and the UK was 42.6%,
while for Austria, Germany, and Switzerland severe
infection affected 24.4%, 30.2% and 40%, respectively
[15,25].
Community-acquired versus nosocomial RVGE In a
study from Austria, Germany, and Switzerland, overall
disease severity scores, by country, were similar in com-
munity-acquired (median score: 9-11) and nosocomial
RVGE (median score: 8-9) [15]. When community-
acquired RVGE and non-RVGE were compared, disease
severity scores were significantly higher for rotavirus-
positive gastroenteritis with a median score of 11 in
Austria (vs 7 for non-rotavirus; P < .001) [31], and a
mean score of 12.14 in France (vs 6.93 for non-rota-
virus, P < .0001) [20].
D e h y d r a t i o ni nc o m m u n i t y - a c q u i r e dR V G EThe
REVEAL study reported that the proportion of children
with dehydration due to acute RVGE varied between
11.1% (Spain) and 71.4% (Sweden), and in most coun-
tries, was considerably higher than for those with rota-
virus-negative disease [34]. In Belgium and the UK, the
prevalence of dehydration was comparable among chil-
dren with or without RVGE [34], whereas the dehydra-
tion prevalence ratio of rotavirus versus non-rotavirus
disease was 1.82, 5.54, 3.27, 3.47, and 2.18, respectively,
i nF r a n c e ,G e r m a n y ,I t a l y ,S p a i n ,a n dS w e d e n[ 3 4 ] .A
second prospective multicenter study from France, Ger-
many, Italy, Spain, and the UK reported that dehydra-
tion was evident in 75.7% of patients with RVGE, and
was severe in 11.3% of them [25]. In comparison, only
54.5% of children with non-RVGE were dehydrated,
while 4.7% had severe dehydration [25]. Another study
from France confirmed this trend, showing significant
differences in dehydration between rotavirus-positive
and negative gastroenteritis (26.8% vs.14.7%, P < .0001)
as did a study from Greece [17,46]. Further, one Italian
community-based study showed that dehydration at
initial presentation in primary care was associated with
a higher likelihood of RVGE (OR: 1.8; 95% CI, 1.1-3; P
= 0.02) [53].
Dehydration in community-acquired versus nosoco-
mial RVGE Only two studies compared the proportion
of patients with dehydration for community-acquired
RVGE with those for nosocomial infection; in both stu-
dies more patients with community-acquired disease
experienced dehydration [43,60]. In an Irish study, 80%
of patients with community-acquired disease were dehy-
drated versus only 55% with nosocomial disease [60].
Likewise, in a study from Sweden, 10.8% of patients
with community-acquired RVGE had either hypertonic
dehydration, or severe dehydration needing intensive
care treatment compared to only 0.8% of patients with
nosocomial RVGE [43].
Mortality
Rotavirus fatalities were rare among young children in
Western Europe with less than 10 deaths occurring per
year in most countries [61], but appeared to pose a
greater risk for children of younger age. For example,
mortality due to nosocomial RVGE was highest among
children less than 12 months of age compared to older
ones (0.74 per 100,000 vs 0.16 per 100,000 children < 5
years per year), as suggested by a study from Spain [29].
Disease burden
Resource utilization
Community-acquired RVGE In the REVEAL study, the
proportions of hospital and emergency referrals among
children presenting at primary care with acute RVGE
ranged from 13.0% (relative risk [RR]: 3.37; 95% confi-
dence interval [CI]: 1.77-6.43) to 57.1% (RR: 2.10; 95%
CI: 0.92-4.75), and from 6.1% to 45.3% (RR: 2.80; 95%
CI: 1.68-4.67), respectively, for all countries included in
the study [34]. Additional country-specific studies
reporting hospital admission rates for community-
acquired disease due to acute RVGE were retrieved
(France 81% [62]; Germany 7% [15]; Italy 11.2% [19];
Spain 9.2% [12]). In Greece, hospital admissions due to
RVGE were significantly more frequent than non-RVGE
(51.4% vs 22% non-rotavirus; P < 0.01) [46].
In the REVEAL study, hospital stay due to acute
RVGE ranged from 2.5 days (Sweden) to 5.0 days in
Germany [34]. In Denmark, 63% of young children hos-
pitalised for rotavirus associated disease stayed for 3
days or less [45]. In France, hospitalization due to
RVGE was longer than for other viral gastroenteritis
cases [63].
Nosocomial RVGE As reported in several studies, noso-
comial rotavirus infection prolonged hospital stay, by 4.4
days in Belgium and Italy (national registry data) [64,65],
and between 9 and 12 days in Ireland [44,60]. In France,
nosocomial RVGE caused statistically significant prolon-
gation of hospital stay, as reported in a prospective
observational multicentre study (10 vs 3.9 days; P <
.001) [26].
Ogilvie et al. BMC Infectious Diseases 2012, 12:62
http://www.biomedcentral.com/1471-2334/12/62
Page 8 of 14Costs
Cost of illness and productivity loss data due to RVGE
was available from several studies in Western Europe
(Table 2).
Hospital setting In the REVEAL study, acute RVGE was
associated with direct medicalc o s t sp e rp a t i e n tr a n g i n g
from $1,942 (UK) to $2,389 (Sweden) (Table 2) [68]. In
the same setting, indirect costs including work days lost
by parents of children hospitalized for RVGE as well as
out-of-pocket expenses ranged between $260 (France)
and $1,061 (UK) [68]. A portion of indirect costs was
attributed to work days lost by parents per hospitaliza-
tion episode, which varied between 2.3 days (France)
and 6.4 days (Germany) [68].
Primary care setting Indirect costs attributed to out-of-
pocket expenses and work days lost by parents of
Table 2 Costs associated with rotavirus acute gastroenteritis in Western Europe, 2009US$
Country/Study Costs per patient National cost estimate per
year (per GDP)
Direct costs Indirect costs Direct costs Indirect costs
Hospital Primary care Home care Hospital Primary care Home care
Austria
Fruhwirth, 2001[66] 384 NRV: 3,752 NA NA NA NA NA NA NA
Belgium
Bilcke, 2009[67] NA NA 22 NA NA NA 10,258,095 (22) 15,372,592 (33)
Bilcke, 2008[64] NA NA 24 NA NA 253 10,832,292 (23) 22,448,225 (48)
Giaquinto, 2007[68] 2,109 110 NA 287 623 NA NA NA
Denmark
Fischer, 2007[45] NA NA NA NA NA NA 2,211,901 (7) NA
France
Fau, 2008[20] 44* NA 271* NA NA NA
Melliez, 2008[24] 1,613 53 10 NA NA NA 33,829,068 (13) NA
Giaquinto, 2007[68] 2,103 121 NA 260 377 NA NA NA
Huet, 2007[69] NA NA NA NA NA NA 152,230,808 (57)
†
Melliez, 2005[70] NA NA NA NA NA NA 35,003,757 (13) NA
Sermet Gaudelus, 2004[71] NRV: 7,185 NA NA NA NA NA NA NA
Piednoir, 2003[27] NRV: 4,534 NA NA NA NA NA NA NA
Germany
Giaquinto, 2007[68] 2,306 146 NA 925 524 NA NA NA
Ireland
Harrington, 2003[60] 1,428 NRV: 7,856 NA NA NA NA NA NA NA
Italy
Marsella, 2009[72] 2,075-2,945 NA NA NA NA NA NA NA
Panatto, 2009[65] 2,076 26 NA NA NA NA 543,775 (0.26) 1,763,070 (0.83)
Giaquinto, 2007[68] 1,982 81 NA 964 372 NA NA NA
Spain
Gil-Prieto, 2009[29] 4,880 NA NA NA NA NA 53,643,376 (37) NA
Lopez-de- Andres, 2008[73] 1,905 NA NA NA NA NA 8,967,305 (6) NA
Luquero Alcalde, 2008[74] 4,505 NA NA NA NA NA NA NA
Giaquinto, 2007[68] 1,973 64 NA 432 194 NA NA NA
Gil, 2004[75] 1,838 NA NA NA NA NA NA NA
Sweden
Giaquinto, 2007[68] 2,389 260 NA 866 716 NA NA NA
UK
Lorgelly, 2008[76] 113 ± 203 NA NA 157 ± 283 NA NA NA NA
Giaquinto, 2007[68] 1,942 141 NA 1,061 440 NA NA NA
NRV: nosocomial rotavirus
*pooled data from hospital & primary care settings
†total including direct and indirect
NB: Indirect costs include work days lost by parents of children hospitalized for RVGE and out-of-pocket expenses; direct medical costs include hospitalization,
outpatient consultation, prescribed & over the counter medication, and medical services (diagnostic, lab tests, etc....)
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$623 (Belgium) (Table 2) [68]. In this setting, work days
lost by parents per episode of RVGE varied between 3.4
days (France) and 7.5 days (UK) [68].
Home care setting Cost data of RVGE management
among children who do not seek medical care is limited
(Table 2) [21,24,64,67]. In France and Belgium, direct
medical costs relating to the routine medical care of
RVGE patients (over-the-counter medication) varied
between $10 and $24 per patient [24,64,67]. A prospec-
tive study estimated the cost of care of children affected
by RVGE while attending day care centers at $27; this
estimate included the cost of over-the-counter medica-
tion, extra diapers, and parent work days lost [21].
Finally, in Belgium, an economic analysis estimated at
$937,231 the annual burden of rotavirus disease among
children less than 7 years of age in the home care set-
ting [67].
National cost estimates In Western Europe, rotavirus
disease incurred direct medical costs of $543,775 (Italy)
[65] to $53.6 million (Spain) [29] each year, and between
$1.7 million (Italy) [65] and $22.4 million (Belgium) [64]
in indirect costs (Table 2).
Discussion
Based on the currently available literature on rotavirus
burden in Western Europe, this analysis revealed that
incidence rates for RVGE in the under five year old
population ranged between 1.33 and 4.96 cases per 100
person-years [15-19]. However, the incidence rate of
RVGE is likely underestimated as many patients receive
care at home. Estimation of the proportion of RVGE
patients receiving no medical care ranged from 25% to
51% of patients [3,23,24]. Accurate estimates of total
incidence rates accounting for all these RVGE cases
were not possible due to the limited availability of epi-
demiological data from community-based cohort studies.
The incidence of nosocomial infection due to RVGE
reported among the hospitalized pediatric population is
higher than the incidence reported in community-based
studies ranging from 0 to 1.87 cases per 1000 days of
hospitalization (0-68.2 per 100 person-years in hospital)
depending on the country [25].
The prevalence of rotavirus infection varied from
country to country. Among the pediatric population,
community-acquired rotavirus infection accounts for
between 25.3% (in Greece) to 63.5% (in Sweden) of
acute gastroenteritis cases [77-79]. These variations may
reflect actual differences in the proportion of RVGE and
incidence of rotaviral disease, however, variations in the
design of the studies captured in the review limits com-
parability across countries. Nosocomial RVGE accounted
for between 47% and 69% of all hospital-acquired acute
gastroenteritis among hospitalized children except in
one study, conducted in France during the peak of the
rotavirus season, where 97% of nosocomial diarrhea
cases were due to rotavirus [15,26,30]. For most coun-
tries in Western Europe, the season for RVGE was
reported to occur in the winter from December to April
or May. A slightly later rotavirus season was noted in
Ireland, Greece and Scandinavian countries. Nosocomial
infection mirrored the seasonality of the community-
acquired disease.
The most commonly isolated genotype combinations
in the Western European region were G1P[8], G2P[4],
and G9P[8] according to the most recent studies avail-
able for each country. G2P[8] and G3P[8] were also
widespread in the region. Genotype combinations G1P
[4], G4P[9], G9P[9], G9P[4], and G2P[10] were each
reported in only one country. Non-typable and partially
typed serotypes accounted for between 0.0% and 3.8% of
all serotypes in studies where these were reported. In
general, the distribution of rotavirus genotype combina-
tions among patients with nosocomial RVGE was very
similar to the distribution among patients with commu-
nity-acquired disease from the same study [15,25,30,49].
While several studies tracked the evolution of geno-
type distribution and predominance over time, we were
not able to discern any overall trends in serotype distri-
bution within the region. This is because serotype pre-
dominance appears to change on a season to season
basis within each country, and may even differ from
region to region within the same country. Emerging
rotavirus serotypes were rarely reported in Italy and
Spain.
Rotavirus fatalities were rare across the region with
less than 10 deaths occurring per year in most countries
among children under five years old; therefore, few stu-
dies included mortality data for RVGE. Mortality due to
nosocomial RVGE was higher, reaching 0.74 per 100,000
children-year among children of less than 12 months of
age compared to 0.16 per 100,000 children-year for
those < 5 years) [29]. Comparison with a global litera-
ture review of mortality due to rotavirus shows that all
o ft h ec o u n t r i e si nW e s t e r nE u r o p eh a v es o m eo ft h e
lowest mortality rates globally [22]. A recent literature
review of rotavirus burden of illness in the Middle East
and North Africa reported annual mortality rates of
between 0 and 112 per 100,000 children under five
years of age depending on the country [80].
Resource utilization by rotavirus infected patients is
generally higher than for non-RVGE related disease.
Hospital admission for gastroenteritis is significantly
more likely to happen in RV induced infections than for
non-RV related disease [46] and, when compared to
non-RVGE, RVGE is associated with significantly higher
disease severity scores [20,31]. Intravenous rehydration
was more commonly administered to patients with
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setting, compared to patients with non-rotavirus disease,
reflecting the higher level of dehydration in RVGE
patients [25,34]. In addition, hospitalization due to
RVGE was longer than for other viral gastroenteritis
causes [63].
Overall, the duration of hospital stay ranged between
2.5 days to 5.0 days for patients with community-
acquired RVGE while nosocomial RVGE infection pro-
longed hospital stay by 4.4 days [68]. However, similar
disease severity scores were reported for community-
acquired and nosocomial RVGE. Little data is available
concerning dehydration in nosocomial cases.
The cost of illness and productivity loss due to RVGE
is large. Overall, at the country level, direct medical
costs due to RVGE ranged between $543,775 and $53.6
million according to the size of the pediatric population
and the type of health care provided, while indirect
costs accounted for an additional $1.7 million to $22.4
million, annually [29,64,65]. Cost per patient varied by
setting, with patients hospitalized for RVGE incurring
the highest direct and indirect costs, and patients trea-
ted at home incurring the lowest costs; however, data
pertaining to the cost of RVGE management among
children who do not seek medical care is limited
[21,24,64,67,68].
Limitations
Study limitations include the lack of available informa-
tion on the burden of RVGE in terms of mortality,
nosocomial diseases and home care; in addition, only
few studies examining morbidity and economic burden
were available, which restricted the evaluation of the
global burden for the region. To describe and compare
serotype distribution across countries, the most recent
available data was considered, however, in some coun-
tries the only available data was not recent and thus did
not cover the same time frame. Finally, the comparabil-
ity of the data reported in this review depends on sev-
eral methodological aspects such as study settings,
period of observation, inclusion criteria for children, and
the definition of nosocomial, which vary from study to
study. Research is this area is ongoing [81-85] and
reflects constant interest in assessing the RVGE burden
i nW e s t e r nE u r o p ei nc o u n t r i es with limited access to
vaccination due to low coverage rates or absence of
country specific recommendations for vaccination.
Conclusion
In conclusion, RVGE is a common disease in Western
Europe affecting the pediatric population. Data on the
burden of RVGE in terms of mortality and home care is
very limited for this region and while data on nosoco-
mial infection is available variations in study setting and
design may affect comparability of data. While 95% of
cases are due to the main five genotypes, analysis of the
evolution of different serotypes over time shows that the
dominance of a certain serotype can change dramatically
from year to year and from country to country. Vaccina-
tion programs may help to reduce the infection rates of
this disease; a vaccine with broad and consistent sero-
type coverage would be important to help decrease the
burden of RVGE in Western Europe.
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